Description and instruction:
to MILDRONATE Caps 250mg # 60″
A drug that improves the metabolism and energy supply of tissues. Oppresses the activity of g-butyrobetaine hydroxylase, reduces the content of free carnitine, reduces the carnitine-dependent oxidation of fatty acids.
The drug improves metabolic processes, increases efficiency, reduces the symptoms of mental and physical overstrain; has a cardioprotective effect. Regulates cellular immunity. Eliminates functional disorders of the nervous system in patients with chronic alcoholism in the abstinence syndrome.
Mildronate promotes the redistribution of blood flow to the ischemic zones, particularly in the brain and retina.
After ingestion, the drug is rapidly absorbed from the digestive tract. Bioavailability is about 78%. C max in plasma is achieved 1-2 hours after administration. T1 / 2 is 3-6 hours.
– decrease in working capacity;
– Physical overstrain (including athletes);
– in the complex therapy of IHD (angina pectoris, myocardial infarction);
– as part of complex therapy of chronic heart failure;
– in the complex therapy of dyshormonal cardiopathy;
– Abstinence syndrome with chronic alcoholism (in combination with specific therapy);
– hemophthalmia and hemorrhages in the retina of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (diabetic, hypertensive);
– in the complex therapy of acute and chronic disorders of blood supply to the brain (stroke, chronic cerebral circulatory failure).
With a decrease in working capacity and physical overstrain (including athletes), adults are prescribed oral 250 mg 4 times a day or IV for 500 mg 1 time / day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.
Athletes are appointed inside by 0.5-1 g 2 times / day before training. The duration of the course in the preparatory period is 14-21 days, during the competition – 10-14 days.
In the complex therapy of coronary artery disease, chronic heart failure, dyshormonal cardiopathy is prescribed by mouth for 250 mg 3 times / day for 3-4 days, then twice a week for 250 mg 3 times / day. The course of treatment is 1-1.5 months.
When chronic alcoholism is prescribed orally 500 mg 4 times / day; in / in and / m – 500 mg 2 times / day. The course of treatment is 7-10 days.
With the pathology of the retinal vessels, dystrophic retinal diseases Mildronate is administered parabulbar by 0.5 ml of 10% solution for 10 days.
If cerebral circulation is disturbed in the acute phase, 500 mg (5 ml of 10% solution) are administered iv every 10 days for 10 days, after which the drug is administered orally at a dose of 500 mg / day. The course of treatment is 2-3 weeks.
If cerebrovascular insufficiency is insufficient for acute disorders, 500 mg (5 ml of 10% solution) are injected IV every 1 day; for chronic disorders – in / m 500 mg (5 ml 10% solution) 1 time / day, then inside 250 mg 1-3 times / day, preferably in the first half of the day. The course of treatment is 2-3 weeks.
If necessary, a repeat course is possible.
From the cardiovascular system: rarely – tachycardia, changes in blood pressure.
From the side of the central nervous system: rarely – psychomotor agitation,
From the digestive system: rarely – dyspeptic phenomena.
Allergic reactions: rarely – skin itching.
– organic diseases of the central nervous system;
– Hypersensitivity to the drug.
Pregnancy and lactation.
The safety of Mildronate in pregnancy is not proven. To avoid possible adverse effects on the fetus, the drug should not be administered during pregnancy.
It is not known whether the drug is excreted in breast milk. If you need to use Mildronate during lactation, breastfeeding should be discontinued.
Currently, there are clinical research data on the use of Mildronate as part of a combination therapy for the regulation of discordant labor, as well as in the complex treatment of placental insufficiency in order to prevent and treat functional disorders of the development of the central nervous system in the fetus.
In clinical studies, the beneficial effect of Mildronate on the state of lipid metabolism (decrease in the content of atherogenic lipids in the blood) was revealed.
The use of the drug in the combination therapy of patients with chronic heart failure increases exercise tolerance.
With caution apply the drug for a long time in patients with chronic liver and kidney diseases.
Use in pediatrics.
Data on the safety and efficacy of Mildronate in children is not enough.
Clinical data on the overdose of Mildronate are absent.